ஐரோப்பிய லுகேமியா நிகர News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐரோப்பிய லுகேமியா நிகர. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐரோப்பிய லுகேமியா நிகர Today - Breaking & Trending Today

Precigen Reports First Quarter 2021 Financial Results

Precigen Reports First Quarter 2021 Financial Results
- Company on track to achieve stated 2021 milestones -
- Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy -
- Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) -
- Upcoming presentation at FOCIS Virtual Annual Meeting to provide clinical progress for AG019 ActoBiotics™ in Type 1 diabetes (T1D) -
News provided by
Share this article
Share this article
GERMANTOWN, Md., May 10, 2021 /PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results. ....

United States , Kevan Herold , Charalamposs Floudas , Steven Harasym , Helen Sabzevari , American Society Of Clinical Oncology , National Cancer Institute , Cancer Research , Research Physician , University Of Washington , Fred Hutchinson Cancer Research Center , Precigen Inc , Federation Of Clinical Immunology Societies , Development Agreement , Yale School Of Medicine , H Lee Moffitt Cancer Center Research Institute , Drug Administration , Exchange Commission , Genitourinary Malignancies Branch , Fred Hutchinson Cancer Research , Preliminary Phase , Moffitt Cancer Center , Orphan Drug Designation , European Leukemia Net , Data Presentation , Clinical Immunology Societies ,

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
- Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic -
- Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs -
- Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity -
- A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria -
- Initiated first AdenoVerse™ immunotherapy clinical trial for PRGN-2009 in HPV-associated solid tumors -
- Interim data for AG019 ActoBiotics™ in T1D indicate encouraging trends in C-peptide levels and ability to induce antigen-specific immune modulation following only one treatment cycle of oral AG019 as monotherapy or combination - ....

United States , Precigen Actobio , Helen Sabzevari , Development Agreement , National Cancer Institute , H Lee Moffitt Cancer Center Research Institute , Drug Administration , Intrexon Corporation , Cancer Research , American Society Of Hematology , University Of Washington , Fred Hutchinson Cancer Research Center , Precigen Inc , Fred Hutchinson Cancer Research , Clinical Data , Moffitt Cancer Center , Drug Designation , Orphan Drug Designation , American Society , European Leukemia Net , Patients Dosed , Cooperative Research , Patient Dosed , Preclinical Data , Six Month Follow Up , Precigen Triple Gene ,